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KEY PO INT S
l Ravulizumab every
8 weeks is noninferior
to eculizumab every
2 weeks across all
efficacy end points
in eculizumab-
experienced PNH
patients.
l Patients with PNH
may be safely and
effectively switched
from labeled-dose
eculizumab every
2 weeks to
ravulizumab every
8 weeks.
Ravulizumab, a new complement component C5 inhibitor administered every 8 weeks, was
noninferior to eculizumab administered every 2 weeks in complement-inhibitor–naive
patients with paroxysmal nocturnal hemoglobinuria (PNH). This study assessed non-
inferiority of ravulizumab to eculizumab in clinically stable PNH patients during previous
eculizumab therapy. In this phase 3, open-label, multicenter study, 195 PNH patients on
labeled-dose (900 mg every 2 weeks) eculizumab for >6 months were randomly assigned
1:1 to switch to ravulizumab (n5 97) or continue eculizumab (n5 98). Primary efficacy end
point was percentage change in lactate dehydrogenase (LDH) from baseline to day 183.
Key secondary end points included proportion of patients with breakthrough hemolysis,
change in Functional Assessment of Chronic Illness Therapy (FACIT)–Fatigue score,
transfusion avoidance, and stabilized hemoglobin. In 191 patients completing 183 days of
treatment, ravulizumab was noninferior to eculizumab (Pinf < .0006 for all end points),
including percentage change in LDH (difference, 9.21% [95% confidence interval (CI),
20.42 to 18.84], P 5 .058 for superiority), breakthrough hemolysis (difference, 5.1 [95%
CI, 28.89 to 18.99]), change in FACIT-Fatigue score (difference, 1.47 [95% CI, 20.21 to
3.15]), transfusion avoidance (difference, 5.5 [95% CI, 24.27 to 15.68]), and stabilized
hemoglobin (difference, 1.4 [95% CI, 210.41 to 13.31]). The most frequently reported adverse event was headache
(26.8%, ravulizumab; 17.3%, eculizumab). No meningococcal infections or discontinuations due to adverse events
occurred. Patients with PNH may be safely and effectively switched from labeled-dose eculizumab administered
every 2 weeks to ravulizumab administered every 8 weeks. This trial was funded by Alexion Pharmaceuticals, Inc.,
and is registered at www.clinicaltrials.gov as #NCT03056040. (Blood. 2019;133(6):540-549)
Introduction
The discovery that uncontrolled complement system activation
plays a key role in the pathogenesis of paroxysmal nocturnal
hemoglobinuria (PNH),1 atypical hemolytic uremic syndrome,2
and myasthenia gravis3,4 was established upon results of several
trials demonstrating the efficacy and safety of complement-
inhibitor therapy to treat these serious and potentially life-
threatening diseases.5-12 Eculizumab (Soliris; Alexion Pharma-
ceuticals, Inc., Boston, MA), the only approved complement in-
hibitor for PNH,13,14 is associated with sustained improvements
in intravascular hemolysis, anemia, thrombotic events, transfu-
sion independence, survival, and quality of life.5-7,15,16 Although
eculizumab therapy is highly effective, up to 27% of eculizumab-
treated patients may experience breakthrough hemolysis,17-19
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resulting in a return of PNH symptoms and increased risk of
serious complications. In addition, the treatment burden asso-
ciated with an every-2-week dosing regimen of an IV infusion
may negatively impact quality of life.20
Ravulizumab (ALXN1210) is a new complement component 5
(C5) inhibitor that produces immediate, complete, and sustained
inhibition of C5 with an extended, 8-week dosing interval.21,22
Ravulizumab binds to C5with high affinity and prevents hemolysis
by inhibiting formation of C5a and C5b.23 In ravulizumab, 4 amino
acid substitutions in the complementarity-determining and Fc
regions of eculizumab result in enhanced endosomal dissocia-
tion of C5 and recycling to the vascular compartment through
the neonatal Fc receptor pathway.22 These modifications result in
a terminal half-life that is approximately fourfold longer than that
of eculizumab.21,22,24
Results of phase 1b/2 studies in complement-inhibitor–naive
patients with PNH demonstrate that ravulizumab provides
rapid and sustained reduction in complement-mediated hemolysis
at dosing intervals up to 12 weeks and overall improvement of
PNH-related symptomatology and quality of life.25 In the largest
phase 3 study in complement-inhibitor–naive PNH patients
conducted to date, ravulizumab was shown to be noninferior to
eculizumab for all end points, including transfusion avoidance,
lactate dehydrogenase (LDH) normalization, percentage change
in LDH levels, change in Functional Assessment of Chronic Ill-
ness Therapy (FACIT)–Fatigue score, breakthrough hemolysis,
and hemoglobin stabilization.26 In this phase 3 study, we assessed
the noninferiority of ravulizumab vs eculizumab in patients with
PNH on stable eculizumab therapy.
Methods
Trial oversight and study design
ALXN1210-PNH-302 was a multicenter, randomized, open-label,
active-controlled study conducted in 49 centers in 11 countries
(registered at www.clinicaltrials.gov as #NCT03056040 and
EudraCT as #2016-002026-36, CHAMPION 302). This study was
performed in accordance with the principles of the Declaration
of Helsinki and the Council for International Organizations of
Medical Sciences International Ethical Guidelines.
The study consisted of a 4-week screening period followed by
a 26-week randomized treatment period and an extension pe-
riod during which all patients received ravulizumab for up to
2 years (supplemental Appendix, section 2; supplemental Fig-
ure 1, available on the Blood Web site). Patients were stratified
according to transfusion history and were randomly assigned (1:1)
to 26 weeks of open-label treatment with IV ravulizumab or
eculizumab. History of major adverse vascular events was not
a component of the randomization stratification criteria. Patients
randomly assigned to the ravulizumab treatment group received
weight-based dosing: a loading dose on day 1 followed by
maintenance doses of ravulizumab (on day 15 and every 8 weeks
thereafter) (supplemental Appendix, section 2; supplemental Fig-
ure 1). Patients randomly assigned to the eculizumab treatment
group received 900 mg every 2 weeks. At the end of the 26-week
treatment period, ravulizumab-treated patients continued weight-
based maintenance dosing of ravulizumab, whereas eculizumab-
treated patients were switched to open-label ravulizumab for the
extension period. Eculizumab-treated patients received aweight-
based loading dose of ravulizumab followed 2 weeks later by
weight-based maintenance doses every 8 weeks.
Patients
The study enrolled adult patients ($18 years of age) who had
documented diagnoses of PNH, confirmed by high-sensitivity
flow cytometry evaluation of red blood cells and white blood
cells with granulocyte or monocyte clone size of $5% and who
were clinically stable on eculizumab treatment. Eligible patients
must have received eculizumab treatment of $6 months at
labeled dose before study entry, had an LDH level #1.53
the upper limit of normal (ULN; 246 U/L) at screening, and
been vaccinated against Neisseria meningitidis ,3 years before
dosing or at the time of study drug initiation to reduce the risk of
meningococcal infections. Key exclusion criteria included LDH
value.23 the ULN in the 6 months before day 1, major adverse
vascular event (supplemental Appendix, section 2) within 6 months
before day 1, platelet count 30 3 109/L, absolute neutrophil
count ,0.5 3 109/L, body weight ,40 kg at screening, history
of bone marrow transplantation, and history of N meningitidis
infection (supplemental Appendix, section 2). All participants
gave written informed consent prior to study participation.
Outcomes
Efficacy end points The primary efficacy end point was hemo-
lysis, as directly measured by percentage change in LDH levels
from baseline to day 183. Key secondary efficacy end points were
proportion of patients with breakthrough hemolysis, defined as
at least 1 new or worsening symptom or sign of intravascular
hemolysis (fatigue, hemoglobinuria, abdominal pain, shortness of
breath [dyspnea], anemia [hemoglobin,10 g/dL], major adverse
vascular event [including thrombosis], dysphagia, or erectile
dysfunction) in the presence of elevated LDH$23 the ULN after
prior reduction of LDH to ,1.53 the ULN on treatment; change
from baseline in quality of life, assessed with the FACIT-Fatigue
Scale Version 4.0; transfusion avoidance, defined as the pro-
portion of patients who remained transfusion free and did not
require a transfusion per protocol-specified guidelines; and pro-
portion of patients with stabilized hemoglobin, defined as
avoidance of a $2-g/dL decrease in hemoglobin level from
baseline in the absence of transfusion.
Additional secondary efficacy end points included total number
of units of packed red blood cells transfused, proportion of
patients with LDH in the normal range, change in European
Organization for Research and Treatment of Cancer Quality of
Life Questionnaire-Core 30 scale (Version 3.0), change in clinical
manifestations of PNH (fatigue, hemoglobinuria, abdominal
pain, shortness of breath, chest pain, dysphagia, and erectile
dysfunction), and proportion of patients experiencing major
adverse vascular events. Change in free C5 concentration over
time was also assessed.
Safety Adverse events were recorded by type, incidence, and
severity. Antidrug antibodies were also assessed. A safety review
committee monitored safety, and an independent data monitoring
committee monitored data for cases of meningococcal infection.
Statistical analysis
The planned sample size of ;192 enrolled patients provided
90% power to demonstrate noninferiority of ravulizumab to
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eculizumab at a 1-sided a level of 0.025, a 10% dropout rate, and
a noninferiority margin of 15% for percentage change in LDH
from baseline to day 183. The primary efficacy end point of
percentage change in LDH from baseline to day 183 was ana-
lyzed by mixed model for repeated measures with the fixed,
categorical effects of treatment, study visit, and study visit by
treatment group interaction as well as the fixed covariate of
baseline LDH and the stratification randomization indicator of
packed red blood cell transfusion history. The Kenward-Roger
approximation was used to estimate denominator degrees of
freedom. A difference in percentage change in LDH frombaseline
to day 183 between ravulizumab and eculizumab treatment
groups along with a 2-sided 95% confidence interval (CI) were
calculated. Ravulizumab treatment was concluded to be non-
inferior to eculizumab if the lower bound of the 95% CI for the
difference (ravulizumab 2 eculizumab) was greater than the
noninferiority margin of 215%.
The key secondary end points were tested for noninferiority in
a hierarchical manner provided that noninferiority was declared
for the primary end point. If noninferiority was established for
all key secondary end points, then superiority was assessed via
a closed-testing procedure, using a 2-sided 0.05 test for each
parameter, in the following order: percentage change in LDH,
FACIT-Fatigue, breakthrough hemolysis, stabilized hemoglobin,
and transfusion avoidance (supplemental Appendix, section 2). If
Table 1. Demographic and baseline clinical characteristics
Characteristic Ravulizumab (n 5 97) Eculizumab (n 5 98) Total (N 5 195)
Sex, no. (%)
Male 50 (51.5) 48 (49.0) 98 (50.3)
Female 47 (48.5) 50 (51.0) 97 (49.7)
Age at first infusion of study drug, mean (SD), y 46.6 (14.4) 48.8 (14.0) 47.7 (14.2)
Race, no. (%)
White 50 (51.5) 61 (62.2) 111 (56.9)
Asian 23 (23.7) 19 (19.4) 42 (21.5)
Japanese 5 (5.2) 7 (7.1) 12 (6.2)
African American 5 (5.2) 3 (3.1) 8 (4.1)
Other/multiple 3 (3.1) 1 (1.0) 4 (2.1)
Not reported/unknown 16 (16.5) 14 (14.3) 30 (15.4)
Weight, mean (SD), kg 72.4 (16.8) 73.4 (14.6) 72.9 (15.7)
Height, mean (SD), cm 168.3 (10.1) 168.8 (9.9) 168.5 (10.0)
Years on eculizumab before first study infusion 6.0 (3.5) 5.6 (3.5) 5.8 (3.5)
Patients with packed red blood cells/whole blood
transfusions received within 1 y before first dose,
no. (%)
13 (13.4) 12 (12.2) 25 (12.8)
Age at PNH diagnosis, mean (SD), y 34.1 (14.4) 36.8 (14.1) 35.5 (14.3)
Time from PNH diagnosis to consent, mean (SD), y 12.4 (8.4) 11.9 (9.4) 12.2 (8.9)
LDH, mean (SD),* U/L 228.0 (48.7) 235.2 (49.7) 231.6 (49.2)
PNH clone size, mean (SD), %
Type II red blood cells 14.9 (19.6) 16.3 (23.6) 15.6 (21.6)
Type III red blood cells† 44.6 (30.5) 43.5 (29.7) 44.0 (30.0)
Total red blood cells 60.6 (32.5) 59.5 (31.4) 60.1 (31.9)
Granulocyte 82.6 (23.6) 84.0 (21.4) 83.3 (22.5)
Monocyte 85.6 (20.5) 86.1 (19.7) 85.9 (20.0)
Hemoglobin, g/L, mean (SD)‡ 110.8 (18.4) 109.1 (18.4) Not available
Haptoglobin, g/L, mean (SD)§ 0.283 (0.235) 0.255 (0.174) Not available
History of major adverse vascular events, no. (%) 28 (28.9) 22 (22.4) 50 (25.6)
History of aplastic anemia, no. (%) 34 (35.1) 39 (39.8) 73 (37.4)
*Normal range, 120 to 246 U/L.
†Erythrocytes with complete deficiency in glycosylphosphatidylinositol-anchored proteins, including complement regulatory proteins CD59 and CD55.30
‡Normal range, 11.5 to 16.0 g/dL (women) and 13.0 to 17.5 g/dL (men).
§Normal range, 0.4 to 2.4 g/dL.
542 blood® 7 FEBRUARY 2019 | VOLUME 133, NUMBER 6 KULASEKARARAJ et al
D
o
w
nloaded from https://ashpublications.org/blood/article-pdf/133/6/540/1750573/blood876805.pdf by RADBOUD UNIVERSITEIT NIJMEGEN user on 10 August 2020
at any point noninferiority or superiority was not reached, then all
subsequent tests were stopped. Post hoc P values were calcu-
lated for testing of noninferiority (Pinf) relative to the prespecified
noninferiority margins to assess the strength of evidence of the
study results.
For the primary end point of percentage change in LDH and
the secondary end point of breakthrough hemolysis, estimates
of the treatment difference were based upon (eculizumab 2
ravulizumab), while the remainder of the end points were based
upon (ravulizumab 2 eculizumab). This calculation was made so
that all positive estimates of treatment effects indicated a greater
effect of ravulizumab, and all negative treatment estimates in-
dicated a greater effect of eculizumab.
Efficacy analyses were performed on the full analysis set (all pa-
tients who received at least 1 dose of ravulizumab or eculizumab).
Safety analyses were performed on the safety set, defined as all
patients who received at least 1 dose of ravulizumab or eculizumab.
The pharmacodynamic analysis was performed on all patients who
received at least 1 dose of study drug and who had evaluable data.
All analyses were performed using SAS release (SAS Institute Inc.,
Cary,NC), version 9.4 or higher, or other validated statistical software.
Results
Patient characteristics
Of 208 patients screened for eligibility, 197 met all entry criteria
and were randomly assigned (1:1) to ravulizumab or eculizumab.
Two patients withdrew before receiving study drug, and 195
received treatment (ravulizumab, n 5 97; eculizumab, n 5 98)
(supplemental Appendix, section 3; supplemental Figure 2).
All received meningococcal vaccination if they had not re-
ceived it in the past 3 years. Of the 195 patients who received
A
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B
Favors ravulizumab
-20 -15 -10 -5 0 5 10 15 20
Favors eculizumab
BTH (%)
Change in FACIT Fatigue
TA (%)
HGB-S (%)
Ravulizumab
(N=97)
0
2.01
87.6
76.3
Eculizumab
(N=98)
5.1
0.54
82.7
75.5
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1.4 (-10.41, 13.31)
Figure 1. Treatment effect. (A) Primary end point. The red triangle indicates the noninferiority margin. [1] Difference (Diff) (95% CI) was based on estimated difference in
percentage with 95% CI. [2] Treatment difference was estimated for eculizumab 2 ravulizumab. (B) Secondary end point. The red triangle indicates the noninferiority margin.
[1] For the end points transfusion avoidance (TA), breakthrough hemolysis (BTH), and stabilized hemoglobin (HGB-S), Diff (95% CI) was based on estimated differences
in percentage with 95% CI. For FACIT-Fatigue, Diff (95% CI) was based on estimated difference in change from baseline with 95% CI. [2] Treatment difference was estimated
for ravulizumab 2 eculizumab, except for breakthrough hemolysis, where treatment difference was based on eculizumab 2 ravulizumab. PCHG, percentage change.
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treatment, 191 completed the 26-week treatment period
(ravulizumab, n 5 96; eculizumab, n 5 95). Four patients
discontinued the study, 1 in the ravulizumab group (patient de-
cision) and 3 in the eculizumab group (patient decision, lack of
efficacy, and pregnancy; n 5 1 for each). Patient demographics
and baseline clinical characteristics were well balanced between
treatment groups (Table 1). On average, patients had received
eculizumab therapy for 5.8 years before study entry. All patients
who received treatment (100%) received all planned infusions of
study medication.
Primary end point
Ravulizumab achieved noninferiority compared with eculizumab
(Figure 1A; Table 2) for the primary end point of percentage
change in LDH, with the point estimate for treatment difference
favoring ravulizumab. The least-squares estimate of the mean
(standard error) in percentage change in LDH from baseline
to day 183 showed a decrease of 0.82% (3.033%) for the
ravulizumab group and an increase of 8.39% (3.041%) for the
eculizumab group, with a treatment difference (ravulizumab 2
eculizumab) of 9.21% (95% CI, 20.42% to 18.84%). The lower
bound of the 95% CI for the difference was 20.42%, which
exceeded the protocol-specified noninferiority margin of 215%,
indicating that ravulizumab is noninferior to eculizumab with
a Pinf , .0006.
Key secondary end points
Treatment with ravulizumab also achieved noninferiority com-
pared with eculizumab for all 4 key secondary end points, with all
point estimates for treatment difference favoring ravulizumab
(Figure 1B; Table 2). No patients in the ravulizumab group ex-
perienced breakthrough hemolysis compared with 5 (5.1%)
patients in the eculizumab group (difference, 5.1% [95% CI,
28.89% to 18.99%, Pinf , .0004). Of these 5 patients with
breakthrough hemolysis, 4 had 1 event each and 1 had 3 events,
the third of which resulted in hospitalization and subsequent study
discontinuation because of lack of efficacy (this patient sub-
sequently received eculizumab 1200 mg every 2 weeks). Four of
the 7 breakthrough hemolysis events were associated with time-
matched free C5$ 0.5mg/mL, a level associated with incomplete
inhibition of hemolysis.13,14 One of these was also associated with
infection. Additionally, 2 events with complete C5 inhibition were
associated with infection. One breakthrough hemolysis event was
of unknown etiology. Least-squares mean (standard error) change
in FACIT-Fatigue total score was 2.01 (0.697) in the ravulizumab
group and 0.54 (0.704) in the eculizumab group (difference, 1.47
[95% CI,20.21 to 3.15], Pinf, .0001). The percentage of patients
with a $3-point improvement in FACIT-Fatigue score was similar
between the ravulizumab and eculizumab groups (37.1% vs
33.7%). Eighty-five of 97 patients (87.6%) receiving ravulizumab
and 81 of 98 patients (82.7%) receiving eculizumab avoided
transfusion, with a between-group difference of 5.5% (95% CI,
24.27% to 15.68%, Pinf , .0001), whereas 74 of 97 patients (76.3%)
receiving ravulizumab and 74 of 98 patients (75.5%) receiving
eculizumab achieved stabilized hemoglobin levels (difference,
1.4% [95% CI, 210.41% to 13.31%], Pinf , .0005).
Because noninferiority was achieved for the primary end point
and all 4 key secondary end points, superiority testing of per-
centage change in LDH was performed. Although LDH levels
increased by 8.4% in the eculizumab group and decreased
0.82% in the ravulizumab group at day 183, the difference did Ta
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not reach statistical significance for superiority (P 5 .058). Ac-
cordingly, no further hierarchical testing was performed.
Subgroup analyses were performed for the randomization strati-
fication variable of transfusion history and for sex, race, region,
and age for the primary end point and key secondary end points.
No sensitive subgroups were identified.
Additional secondary end points
The mean (standard deviation [SD]) total number of packed
red blood cell units transfused during the treatment period
was comparable in the ravulizumab (4.3 [4.76]) and eculizumab
(3.4 [3.01]) treatment groups (Table 3). As expected in a patient
population that was clinically stable on eculizumab therapy, the
proportion of patients who achieved normalization in LDH was
relatively stable over time. At day 183, LDH normalization was
achieved by 64 of 97 patients (66.0%) treated with ravulizumab
and 58 of 98 patients (59.2%) treated with eculizumab (Figure 2).
Similarly, mean LDH values were within the normal range at
baseline and generally sustained over time (supplemental Ap-
pendix, section 3; supplemental Figure 3). Baseline European
Organization for Research and Treatment of Cancer Quality of Life
Questionnaire-Core 30 subscale scores reflected a patient pop-
ulation with stable disease, and changes in scores during the study
were similar in both treatment groups (supplemental Appendix,
section 4; supplemental Table 1). Similarly, shifts in clinical mani-
festations of PNH were infrequent in both treatment groups,
and no patient experienced a major adverse vascular event
(Table 3).
Mean serum free C5 concentrations were suppressed to,0.5 mg/mL
by the end of the first infusion and at all subsequent visits for all
patients receiving ravulizumab; however, this threshold was not
consistently met in the eculizumab group (Figure 3).
Safety and tolerability
Ravulizumab and eculizumab were well tolerated in this study.
An overview of adverse events is shown in Table 4. The most
frequently reported adverse event occurring in 3% or more of
patients in either treatment group was headache, which occurred
in 26.8% of patients treated with ravulizumab and in 17.3% of
patients treated with eculizumab. Twelve patients experienced
Table 3. Other secondary efficacy outcomes at day 183
Ravulizumab (n 5 96) Eculizumab (n 5 95)
Total number of packed red blood cell units
transfused, mean (SD)
— 4.3 (4.76)† — 3.4 (3.01)‡
Patients with major adverse vascular events, n (%) — 0 (0) — 0 (0)
Baseline* Day 183 Baseline* Day 183
Clinical manifestations of PNH, n (%)
Fatigue 29 (30.2) 42 (43.8) 38 (40) 36 (37.9)
Abdominal pain 5 (5.2) 5 (5.2) 6 (6.3) 12 (12.6)
Dyspnea 6 (6.3) 6 (6.3) 10 (10.5) 17 (17.9)
Dysphagia 2 (2.1) 5 (5.2) 2 (2.1) 5 (5.2)
Chest pain 0 (0) 2 (2.1) 1 (1.1) 5 (5.2)
Hemoglobinuria 4 (4.2) 8 (8.3) 7 (7.4) 9 (9.5)
Erectile dysfunction§ 5 (10.0) 6 (12.0) 7 (14.6) 6 (12.5)
*Baseline was defined as the last nonmissing value before the first dose of study drug.
†n 5 97.
‡n 5 98.
§n 5 50 male patients in the ravulizumab group and n 5 48 male patients in the eculizumab group.
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Figure 2. Percentage of patients achieving LDH nor-
malization over time in the ravulizumab and eculizu-
mab treatment groups. LDH normalization is defined as
proportion of patients who achieved LDH level #13 the
ULN (246 U/L).
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serious adverse events (4 ravulizumab patients and 8 eculizumab
patients). Pyrexia and hemolysis were the only serious adverse
events reported by.1 patient (3 and 2 patients, respectively, all in
the eculizumab group). There were no deaths and no cases of
meningococcal infection. Serious infections occurred in 2 patients
(2.1%) in the ravulizumab group (influenza and lower respiratory
tract infection [without positive culture]) and in 1 eculizumab-
treated patient (1.0%) (acute pyelonephritis [causative agent un-
known]). None of these serious adverse events led to discon-
tinuation from the study. Four patients discontinued the study,
1 in the ravulizumab group (withdrawal by subject) and 3 in the
eculizumab group (withdrawal by subject, lack of efficacy
[3 breakthrough hemolysis events], and pregnancy). No adverse
events led to withdrawal of study drug during the randomized
treatment period. There were no treatment-emergent anti-
drug antibodies in patients treated with ravulizumab.
Discussion
This 26-week, active-controlled study of 195 patients with PNH
whowere clinically stable on labeled-dose eculizumab treatment
for a mean for 5.8 years demonstrated that ravulizumab ad-
ministered every 8 weeks effectively inhibited complement-
mediated hemolysis and had a safety profile similar to that of
eculizumab.5-7 Ravulizumab met the primary end point (per-
centage change in LDH from baseline to day 183) and all key
secondary end points, showing noninferiority to biweekly
treatment with 900 mg eculizumab, the current standard of care
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Figure 3. Mean (95% CI) free C5 levels in the ravulizumab and eculizumab groups over time. (A-B) A gyros-based fluorescence assay was used for patients who received
ravulizumab (A), and an electrochemiluminescence immunoassay was used for patients who received eculizumab (B). Baseline (BL) is defined as the last nonmissing value before
first dose of study drug. Day 29, 43, 57, 85, 99, 113, 141, 155, and 169 data are from anytime for the ravulizumab group and predose for the eculizumab group. Horizontal line
indicates free C5 level of 0.5 mg/mL. Free C5 levels ,0.5 mg/mL are associated with complete inhibition of C5 activity.
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for PNH.13,14 Point estimates consistently favored ravulizumab
treatment over eculizumab treatment for the primary end point
and all 4 key secondary efficacy end points, although none of the
results from this noninferiority trial demonstrated superiority.
Given that the patients enrolled in this study were stable on
eculizumab therapy and LDH levels were within the normal
range at baseline, and given the highly efficacious nature of
eculizumab, differences between treatments were expected to
be minimal.15-17 However, 5 patients receiving eculizumab experi-
enced breakthrough hemolysis, whereas no events of breakthrough
hemolysis were observed in patients switched to ravulizumab.
Among 7 episodes of breakthrough hemolysis, 4 were associ-
ated with inadequate C5 inhibition, 2 were primarily associated
with infection, and 1was of unclear etiology. Breakthrough hemolysis
occurring as a result of complement-amplifying conditions such as
infection may occur irrespective of free C5 and remains a pos-
sibility with the use of eculizumab and ravulizumab. Moreover,
nomajor adverse vascular events were observed in either treatment
group.
These results are qualitatively similar to those observed in
patients naive to C5 inhibitor therapy,26 providing further
evidence that ravulizumab provides complete inhibition of
C5 to levels ,0.5 mg/mL compared with eculizumab, which
did not provide complete inhibition in all patients, and may
mitigate the observed incidence and clinical sequelae of break-
through hemolysis that has been observed with labeled-dose
eculizumab.17-19
The safety profile of ravulizumab was consistent with that of
eculizumab in the clinical trial program in PNH.5,7,27 Overall,
the types and incidences of adverse events were comparable
to those of other ravulizumab25,26 and eculizumab trials,5,7,27
with headache being the most commonly reported adverse
event. The serious infections noted in this study resolved with-
out sequelae. Although an increased risk of meningococcal
infections has been reported in recipients of complement in-
hibitor therapy,13,14,28,29 no such infections were observed in the
present trial.
This study demonstrates that patients with PNH may be safely
and effectively switched from eculizumab (900 mg administered
every 2 weeks) to ravulizumab administered every 8 weeks while
maintaining the high level of efficacy, safety, and quality of life
previously achieved with eculizumab. For all efficacy end points,
ravulizumab achieved noninferiority compared with eculizumab.
The complete and sustained C5 inhibition associated with
ravulizumab may account for the consistent results across end
points. For stable patients receiving label-dose eculizumab ther-
apy, providing an effective treatment duration that is 4 times
longer between infusions by switching to ravulizumab given
every 8 weeks is likely to result in a substantially reduced burden
of treatment, fewer occurrences of breakthrough hemolysis and
their clinical consequences, better quality of life, and greater
likelihood of retention on long-term therapy.
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Patients with serious adverse
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Patients with adverse events
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Patients with serious adverse
events leading to withdrawal of
study drug
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Values are reported as n (%) of patients.
RAVULIZUMAB IN ECULIZUMAB-EXPERIENCED PNH PATIENTS blood® 7 FEBRUARY 2019 | VOLUME 133, NUMBER 6 547
D
o
w
nloaded from https://ashpublications.org/blood/article-pdf/133/6/540/1750573/blood876805.pdf by RADBOUD UNIVERSITEIT NIJMEGEN user on 10 August 2020
approved the final version; E.B. contributed to the study protocol,
contributed to the manuscript, and approved the final version; and A.R.
and R.P.d.L. developed the protocol, recruited patients, collected
data, analyzed and interpreted the data, contributed to the manuscript,
and approved the final version.
Conflict-of-interest disclosure: A.G.K., A.H., R.W., F.A.G.-F., A.G., E.O.G.,
A.R., and S.N. have received honoraria and consulting fees from
Alexion Pharmaceuticals, Inc. S.T.R., L.S., A.I.D., and S.O. are
employees and stockholders of Alexion Pharmaceuticals, Inc. J.W.L. has
received honoraria, consulting fees, and research support (to Seoul
St. Mary’s Hospital) from Alexion Pharmaceuticals, Inc. E.B. is a former
employee and stockholder of Alexion Pharmaceuticals, Inc. J.S. has
received consultancies, honoraria, and advisory board membership for
Alexion Pharmaceuticals, Inc. A.R. has received consultancies and hon-
oraria from Alexion, Roche, and Novartis and research funding from
Alexion and Roche. R.P.d.L. has received consultancies, honoraria, and
research funding from Alexion, Novartis, and Pfizer and research
funding from Amgen. The remaining authors declare no competing
financial interests.
A complete list of study investigators can be found in the supplemental
Appendix, section 1.
Correspondence: Austin G. Kulasekararaj, Department of Haemato-
logical Medicine, King’s College Hospital, NHS Foundation Trust,
Denmark Hill, London SE5 9RS, United Kingdom; e-mail: austin.kula-
sekararaj@nhs.net.
Footnotes
Submitted 26 September 2018; accepted 18 November 2018. Pre-
published online as Blood First Edition paper, 3 December 2018; DOI
10.1182/blood-2018-09-876805.
Presented at 60th annual meeting of the American Society of Hema-
tology, San Diego, CA, 1-4 December 2018.
Qualified academic investigatorsmay request participant-level, de-identified
clinical data and supporting documents (statistical analysis plan and protocol)
pertaining to this study. Further details regarding data availability, instruc-
tions for requesting information, and our data disclosure policy are available
at the Alexion Web site (http://alexion.com/research-development).
The online version of this article contains a data supplement.
There is a Blood Commentary on this article in this issue.
The publication costs of this article were defrayed in part by page charge
payment. Therefore, and solely to indicate this fact, this article is hereby
marked “advertisement” in accordance with 18 USC section 1734.
REFERENCES
1. Brodsky RA. Paroxysmal nocturnal he-
moglobinuria.Blood. 2014;124(18):2804-2811.
2. Zhang K, Lu Y, Harley KT, Tran MH. Atypical
hemolytic uremic syndrome: a brief review.
Hematol Rep. 2017;9(2):7053.
3. Phillips WD, Vincent A. Pathogenesis of my-
asthenia gravis: update on disease types,
models, and mechanisms. F1000 Res. 2016;5:
F1000 Faculty Rev-1513.
4. Farmakidis C, Pasnoor M, Dimachkie MM,
Barohn RJ. Treatment of myasthenia gravis.
Neurol Clin. 2018;36(2):311-337.
5. Hillmen P, Young NS, Schubert J, et al. The
complement inhibitor eculizumab in parox-
ysmal nocturnal hemoglobinuria. N Engl
J Med. 2006;355(12):1233-1243.
6. Hillmen P, Muus P, Du¨hrsen U, et al. Effect of
the complement inhibitor eculizumab on
thromboembolism in patients with paroxysmal
nocturnal hemoglobinuria. Blood. 2007;
110(12):4123-4128.
7. Brodsky RA, Young NS, Antonioli E, et al.
Multicenter phase 3 study of the complement
inhibitor eculizumab for the treatment of
patients with paroxysmal nocturnal hemo-
globinuria. Blood. 2008;111(4):1840-1847.
8. Legendre CM, Licht C, Muus P, et al. Terminal
complement inhibitor eculizumab in atypical
hemolytic-uremic syndrome. N Engl J Med.
2013;368(23):2169-2181.
9. Licht C, Greenbaum LA, Muus P, et al. Efficacy
and safety of eculizumab in atypical hemolytic
uremic syndrome from 2-year extensions of
phase 2 studies. Kidney Int. 2015;87(5):
1061-1073.
10. Greenbaum LA, Fila M, Ardissino G, et al.
Eculizumab is a safe and effective treatment in
pediatric patients with atypical hemolytic
uremic syndrome. Kidney Int. 2016;89(3):
701-711.
11. Fakhouri F, Hourmant M, Campistol JM, et al.
Terminal complement inhibitor eculizumab in
adult patients with atypical hemolytic uremic
syndrome: A single-arm, open-label trial. Am
J Kidney Dis. 2016;68(1):84-93.
12. Howard JF Jr, Utsugisawa K, Benatar M, et al;
REGAIN Study Group. Safety and efficacy of
eculizumab in anti-acetylcholine receptor
antibody-positive refractory generalised
myasthenia gravis (REGAIN): a phase 3, rand-
omised, double-blind, placebo-controlled,
multicentre study. Lancet Neurol. 2017;16(12):
976-986.
13. Soliris [summary of product characteristics].
Paris, France: Alexion Europe SAS; 2017.
14. Soliris [prescribing information]. Boston, MA:
Alexion Pharmaceuticals, Inc.; 2018.
15. Loschi M, Porcher R, Barraco F, et al. Impact
of eculizumab treatment on paroxysmal noc-
turnal hemoglobinuria: a treatment versus
no-treatment study. Am J Hematol. 2016;91(4):
366-370.
16. Kelly RJ, Hill A, Arnold LM, et al. Long-term
treatment with eculizumab in paroxysmal
nocturnal hemoglobinuria: sustained efficacy
and improved survival. Blood. 2011;117(25):
6786-6792.
17. Hill A, Kelly RJ, Hillmen P. Thrombosis in
paroxysmal nocturnal hemoglobinuria. Blood.
2013;121(25):4985-4996, quiz 5105.
18. Nakayama H, Usuki K, Echizen H, Ogawa R,
Orii T. Eculizumab dosing intervals longer
than 17 days may be associated with greater
risk of breakthrough hemolysis in patients with
paroxysmal nocturnal hemoglobinuria. Biol
Pharm Bull. 2016;39(2):285-288.
19. Peffault de Latour R, Fremeaux-Bacchi V,
Porcher R, et al. Assessing complement
blockade in patients with paroxysmal noctur-
nal hemoglobinuria receiving eculizumab.
Blood. 2015;125(5):775-783.
20. Groth M, Singer S, Niedeggen C, et al.
Development of a disease-specific quality of
life questionnaire for patients with aplastic
anemia and/or paroxysmal nocturnal hemo-
globinuria (QLQ-AA/PNH)-report on phases I
and II. Ann Hematol. 2017;96(2):171-181.
21. Sahelijo L, Mujeebudin A, Mitchell D, et al.
First in human single-ascending dose study:
safety, biomarker, pharmacokinetics and
exposure-response relationships of
ALXN1210, a humanized monoclonal anti-
body to C5, with marked half-life extension
and potential for significantly longer dosing
intervals [abstract]. Blood. 2015;126(23).
Abstract 4777.
22. Sheridan D, Yu ZX, Zhang Y, et al. Design and
preclinical characterization of ALXN1210: A
novel anti-C5 antibody with extended duration
of action. PLoS One. 2018;13(4):e0195909.
23. Hill A, DeZern AE, Kinoshita T, Brodsky RA.
Paroxysmal nocturnal haemoglobinuria. Nat
Rev Dis Primers. 2017;18:3:17028.
24. Lee JW, Bachman ES, Aguzzi R, et al.
Immediate, complete, and sustained in-
hibition of C5 with ALXN1210 reduces
complement-mediated hemolysis in patients
with paroxysmal nocturnal hemoglobinuria
(PNH): interim analysis of a dose-escalation
study [abstract]. Blood. 2016;128(22). Abstract
2428.
25. Ro¨th A, Rottinghaus ST, Hill A, et al.
Optimization of dose regimen for ALXN1210,
a novel complement C5 inhibitor, in patients
with paroxysmal nocturnal hemoglobinuria
(PNH): Results of 2 phase 1/2 studies
[abstract]. Blood. 2017;130(suppl 1).
Abstract 3482.
26. Lee JW, de Fontbrune FS, Lee LWL, et al.
Ravulizumab (ALXN1210) vs eculizumab in
adult patients with PNH naive to complement
inhibitors: the 301 study. Blood. 2019;133(6):
530-539.
27. Hillmen P,Muus P, Ro¨thA, et al. Long-term safety
and efficacy of sustained eculizumab treatment
548 blood® 7 FEBRUARY 2019 | VOLUME 133, NUMBER 6 KULASEKARARAJ et al
D
o
w
nloaded from https://ashpublications.org/blood/article-pdf/133/6/540/1750573/blood876805.pdf by RADBOUD UNIVERSITEIT NIJMEGEN user on 10 August 2020
in patients with paroxysmal nocturnal haemo-
globinuria. Br J Haematol. 2013;162(1):62-73.
28. McNamara LA, Topaz N, Wang X, Hariri S, Fox
L, MacNeil JR. High risk for invasive menin-
gococcal disease among patients receiving
eculizumab (Soliris) despite receipt of
meningococcal vaccine. MMWR Morb Mortal
Wkly Rep. 2017;66(27):734-737.
29. Hill A, Ro¨th A, Socie G, et al. Interim analysis
of safety outcomes during treatment with
eculizumab: results from the International Par-
oxysmal Nocturnal Hemoglobinuria Registry
[abstract]. Blood. 2017;130(suppl 1).
Abstract 3486.
30. Risitano AM, Rotoli B. Paroxysmal nocturnal
hemoglobinuria: pathophysiology, natural
history and treatment options in the era of
biological agents. Biologics. 2008;2(2):205-222.
RAVULIZUMAB IN ECULIZUMAB-EXPERIENCED PNH PATIENTS blood® 7 FEBRUARY 2019 | VOLUME 133, NUMBER 6 549
D
o
w
nloaded from https://ashpublications.org/blood/article-pdf/133/6/540/1750573/blood876805.pdf by RADBOUD UNIVERSITEIT NIJMEGEN user on 10 August 2020
